Amorfix Aggregated Aβ Assay (A4) Service

Alzheimer's disease (AD) is the most common of all chronic neurodegenerative diseases. While no one knows exactly what causes AD, it is associated with deposits of Aβ aggregates in the brain, known as amyloid. It is believed that Aβ aggregates result from abnormal production and accumulation of the Aβ peptide.

The Amorfix Aggregated Aβ Assay (A4) detects the presence of aggregated Aβ in standard animal models of AD several months before conventional microscopic procedures, and hence can accelerate the preclinical screening of new treatments for AD. In addition, the assay is significantly more sensitive than current methods for detecting total Aβ and can be used in high-throughput applications designed to study the inhibition of Aβ aggregation for new drug discovery.

A4 can provide a quantitative measure of Aβ aggregates in mice before plaques are detected using immunohistochemistry.

Download our A4 presentation here.

Advantages of the A4 for Drug Development

  • Provides quantitative and sensitive measurements of Aβ aggregates in AD mouse brains
  • Detects Aβ aggregates several months sooner than immunohistochemistry (IHC)
  • Validated in 8 AD mouse models
  • Reduces animal trial time and costs
  • Compatible with cell culture studies for drug discovery
  • Assess efficacy of therapeutics faster
  • High through-put compatible, allows screening for more lead candidates